These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28911065)

  • 21. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
    Basch E; Rogak LJ; Dueck AC
    Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Supporting quality and patient safety in cancer clinical trials.
    Badalucco S; Reed KK
    Clin J Oncol Nurs; 2011 Jun; 15(3):263-5. PubMed ID: 21624861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
    Atkinson TM; Ryan SJ; Bennett AV; Stover AM; Saracino RM; Rogak LJ; Jewell ST; Matsoukas K; Li Y; Basch E
    Support Care Cancer; 2016 Aug; 24(8):3669-76. PubMed ID: 27260018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
    Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.
    Banerjee AK; Okun S; Edwards IR; Wicks P; Smith MY; Mayall SJ; Flamion B; Cleeland C; Basch E;
    Drug Saf; 2013 Dec; 36(12):1129-49. PubMed ID: 24092596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic.
    Gilbert A; Sebag-Montefiore D; Davidson S; Velikova G
    Gynecol Oncol; 2015 Mar; 136(3):429-39. PubMed ID: 25448486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detecting adverse drug reactions in discharge summaries of electronic medical records using Readpeer.
    Tang Y; Yang J; Ang PS; Dorajoo SR; Foo B; Soh S; Tan SH; Tham MY; Ye Q; Shek L; Sung C; Tung A
    Int J Med Inform; 2019 Aug; 128():62-70. PubMed ID: 31160013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Basch E; Becker C; Rogak LJ; Schrag D; Reeve BB; Spears P; Smith ML; Gounder MM; Mahoney MR; Schwartz GK; Bennett AV; Mendoza TR; Cleeland CS; Sloan JA; Bruner DW; Schwab G; Atkinson TM; Thanarajasingam G; Bertagnolli MM; Dueck AC
    Clin Trials; 2021 Feb; 18(1):104-114. PubMed ID: 33258687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.
    Basch E; Iasonos A; Barz A; Culkin A; Kris MG; Artz D; Fearn P; Speakman J; Farquhar R; Scher HI; McCabe M; Schrag D
    J Clin Oncol; 2007 Dec; 25(34):5374-80. PubMed ID: 18048818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment.
    Moradian S; Ghasemi S; Boutorabi B; Sharifian Z; Dastjerdi F; Buick C; Lee CT; Mayo SJ; Morita PP; Howell D
    Cancer Inform; 2023; 22():11769351231178587. PubMed ID: 37313372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - a feasibility study.
    Taarnhøj GA; Lindberg H; Dohn LH; Omland LH; Hjøllund NH; Johansen C; Pappot H
    Health Qual Life Outcomes; 2020 Jul; 18(1):225. PubMed ID: 32653005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians.
    Reeve BB; Withycombe JS; Baker JN; Hooke MC; Lyons JC; Mowbray C; Wang J; Freyer DR; Joffe S; Sung L; Tomlinson D; Gold SH; Hinds PS
    Pediatr Blood Cancer; 2013 Jul; 60(7):1231-6. PubMed ID: 23335328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
    Basch E; Iasonos A; McDonough T; Barz A; Culkin A; Kris MG; Scher HI; Schrag D
    Lancet Oncol; 2006 Nov; 7(11):903-9. PubMed ID: 17081915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation Between Remote Symptom Reporting by Caregivers and Adverse Clinical Outcomes: Mixed Methods Study.
    Oakley-Girvan I; Yunis R; Fonda SJ; Longmire M; Veuthey TL; Shieh J; Aghaee S; Kubo A; Davis SW; Liu R; Neeman E
    J Med Internet Res; 2023 Nov; 25():e49100. PubMed ID: 37988151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems.
    Hassett MJ; Cronin C; Tsou TC; Wedge J; Bian J; Dizon DS; Hazard-Jenkins H; Osarogiagbon RU; Wong S; Basch E; Austin T; McCleary N; Schrag D
    JCO Clin Cancer Inform; 2022 Jan; 6():e2100137. PubMed ID: 34985914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Kluetz PG; Chingos DT; Basch EM; Mitchell SA
    Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electronic toxicity monitoring and patient-reported outcomes.
    Basch EM; Reeve BB; Mitchell SA; Clauser SB; Minasian L; Sit L; Chilukuri R; Baumgartner P; Rogak L; Blauel E; Abernethy AP; Bruner D
    Cancer J; 2011; 17(4):231-4. PubMed ID: 21799330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities.
    Basch E; Artz D; Iasonos A; Speakman J; Shannon K; Lin K; Pun C; Yong H; Fearn P; Barz A; Scher HI; McCabe M; Schrag D
    J Am Med Inform Assoc; 2007; 14(3):264-8. PubMed ID: 17329732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
    Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
    Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.